Shares of Affymax Inc. (Nasdaq: AFFY) continued rising by soaring 37 cents to close at $1.81 after a Seeking Alpha contributor expressed confidence that the biopharmaceutical would successfully address safety concerns of its anemia drug Omontys.
Affymax Continues Rising
May 09, 2013 at 17:23 PM EDT
